Gain Therapeutics, Inc. (GANX)
Data as of , from SEC Form 4 filings.
See up to 3 months of GANX. The 7-day demo opens the 1M and 3M ranges and puts GANX on your watchlist.
Start 7-day demoLatest GANX insider trades
About Gain Therapeutics, Inc. (GANX)
Gain Therapeutics, Inc. files with the SEC under CIK 0001819411 and is classified as pharmaceutical preparations. We track it alongside the rest of the Health Care sector.
GANX Form 4 activity by transaction type, last 90 days
No Form 4 activity for GANX in the last 90 days.
GANX insider transactions (Form 4)
1010 Form 4 filings on record, the earliest from Jun 24, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Dov A. Md Goldstein - Director | Grant or award | Stock Option (right to buy) | 25,000 | $0.00 | - | |
| Claude Nicaise - Director | Grant or award | Stock Option (right to buy) | 25,000 | $0.00 | - | |
| Khalid Islam - Director | Grant or award | Stock Option (right to buy) | 25,000 | $0.00 | - | |
| Gwen A. Melincoff - Director | Grant or award | Stock Option (right to buy) | 25,000 | $0.00 | - | |
| Jeffrey Scott Riley - Director | Grant or award | Stock Option (right to buy) | 25,000 | $0.00 | - | |
| Hans Peter Hasler - Director | Grant or award | Stock Option (right to buy) | 25,000 | $0.00 | - | |
| Gene Mack - Officer | Grant or award | Employee Stock Option (right to buy) | 200,000 | $0.00 | - | |
 Gianluca Fuggetta - Officer | Grant or award | Employee Stock Option (right to buy) | 50,000 | $0.00 | - | |
| Hans Peter Hasler - Director | Grant or award | Stock Option (right to buy) | 15,000 | $0.00 | - | |
| Dov A. Md Goldstein - Director | Grant or award | Stock Option (right to buy) | 15,000 | $0.00 | - |
GANX insider trading FAQ
What is the latest insider trade for GANX?
Gain Therapeutics, Inc. (GANX) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-07-17. The full record for GANX runs to 10 Form 4 filings, the earliest from 2025-06-24. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying GANX stock?
No insider purchases of GANX were filed in the last 90 days.
How many insiders are selling GANX stock?
No insider sales of GANX were filed in the last 90 days.
Where can I see GANX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects GANX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Dov A. Md Goldstein view on EDGAR
- - Claude Nicaise view on EDGAR
- - Khalid Islam view on EDGAR
- - Gwen A. Melincoff view on EDGAR
- - Jeffrey Scott Riley view on EDGAR
- - Hans Peter Hasler view on EDGAR
- - Gene Mack view on EDGAR
- - Gianluca Fuggetta view on EDGAR
- - Hans Peter Hasler view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where GANX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow GANX with a 7-day demo
- GANX on your watchlist
- Every GANX Form 4 filing on record
- Up to 3 months of GANX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
